Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group.

J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1125-32. doi: 10.1136/jnnp-2012-302468. Epub 2012 Jul 12.

PMID:
22791906
2.
3.
4.

[Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].

Wissel J, Entner T.

Wien Klin Wochenschr. 2001;113 Suppl 4:20-4. Review. German.

PMID:
15506048
5.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
6.
7.

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Trebst C, Stangel M.

Fortschr Neurol Psychiatr. 2005 Aug;73(8):463-9. Review. German.

PMID:
16052440
8.

[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].

Oreja-Guevara C.

Rev Neurol. 2012 Oct 1;55(7):421-30. Review. Spanish.

9.

What place for ▾ cannabis extract in MS?

[No authors listed]

Drug Ther Bull. 2012 Dec;50(12):141-4. doi: 10.1136/dtb.2012.11.0150. Review.

PMID:
23241565
10.

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.

Russo EB, Guy GW, Robson PJ.

Chem Biodivers. 2007 Aug;4(8):1729-43. Review.

PMID:
17712817
11.

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.

Lakhan SE, Rowland M.

BMC Neurol. 2009 Dec 4;9:59. doi: 10.1186/1471-2377-9-59. Review.

12.

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Oreja-Guevara C.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Review.

PMID:
22509985
13.

[Marihuana and cannobinoids as medicaments].

Tkaczyk M, Florek E, Piekoszewski W.

Przegl Lek. 2012;69(10):1095-7. Review. Polish.

PMID:
23421098
14.

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Pozzilli C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Review.

PMID:
24289844
16.

Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.

Arroyo R, Vila C, Dechant KL.

J Comp Eff Res. 2014 Jul;3(4):435-44. doi: 10.2217/cer.14.30. Review.

PMID:
25275238
17.

A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.

Flachenecker P.

Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):15-9. doi: 10.1586/ern.13.1. Review.

PMID:
23369055
18.

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.

Podda G, Constantinescu CS.

Expert Opin Biol Ther. 2012 Nov;12(11):1517-31. doi: 10.1517/14712598.2012.721765. Epub 2012 Sep 7. Review.

PMID:
22954177
19.

Pathophysiology, assessment and management of multiple sclerosis spasticity: an update.

Haas J.

Expert Rev Neurother. 2011 Apr;11(4 Suppl):3-8. Review.

PMID:
21449853
20.

Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.

Meuth SG, Vila C, Dechant KL.

Expert Rev Neurother. 2015;15(8):909-18. doi: 10.1586/14737175.2015.1067607. Epub 2015 Jul 11. Review.

PMID:
26166264

Supplemental Content

Support Center